References
- Centers for Disease Control and Prevention. Updated US Public Health Service Guidelines for management of occu-pational exposures to HBV, HCV, and HIV and recommenda-tions for post exposure prophylaxis. MMWR Morb Mortal Wkly Rep 2001; 50: 1–52.
- Bassett IV, Freedberg KA, Walensky RP. Two drugs or three? Balancing efficacy, toxicity, and resistance in post exposure prophylaxis for occupational exposure to HIV. Clin Infect Dis 2004; 39: 395–401.
- Haas DW, Ribaudo HJ, Richard KB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: and adult AIDS clinical trials group study. AIDS 2004; 18 (18): 2391–2400.
- Rodriguez-Novoa S, Barriero P, Jimênez-Nacher Inmaculada, Gonzalez-Lahoz, Soriano V. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoen-zyme on efavirenz plasma concentrations in HIV-infected sub-jects. Clinic Infect Dis 2005; 40: 1358–1361.
- Blanch J, Corbella B, Garcia F, Parellada E, Gatell JM. Maniac syndrome associated with efavirenz overdose. Clin Infect Dis 2001; 33: 270–271.
- Wright AA, Katz IT. Bar coding for patient safety. NEJM 2005; 353: 329–331.